Cytokinetics, Incorporated
CYTK
$59.32
-$0.68-1.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 817.10% | -97.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 817.10% | -97.10% | |||
| Cost of Revenue | 5.20% | -11.84% | |||
| Gross Profit | 10.95% | -112.51% | |||
| SG&A Expenses | 32.06% | 5.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.26% | -5.38% | |||
| Operating Income | -6.96% | -49.55% | |||
| Income Before Tax | 40.22% | -127.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 40.22% | -127.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 40.22% | -127.86% | |||
| EBIT | -6.96% | -49.55% | |||
| EBITDA | -6.97% | -50.22% | |||
| EPS Basic | 40.28% | -126.88% | |||
| Normalized Basic EPS | 79.84% | -126.87% | |||
| EPS Diluted | 40.28% | -126.88% | |||
| Normalized Diluted EPS | 79.84% | -126.87% | |||
| Average Basic Shares Outstanding | 0.10% | 0.44% | |||
| Average Diluted Shares Outstanding | 0.10% | 0.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||